Key facts
- Sweetech (Drug Discovery)’s last known valuation is $2.2M (Oct 2023).
- It has raised $2.9M; the latest was Seed Round ($2.6M) in Jan 2026.
- Notable investors include Bpifrance, Iron Hands Capital, Nubbo, Toulouse Tech Transfer.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Sweetech (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Sweetech (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sweetech (Drug Discovery)
Developer of medical applications designed to improve human health. The company produces and markets sugar via innovative and patented fermentation processes to offer, on an industrial scale, several oligosaccharides with high potential for health applications, enabling clients to target the production and sales of rare and high-added-value oligosaccharides through the development of innovative and patented fermentation processes.
- Sector
- Healthcare
- HQ
- Leguevin, France
- Founded
- 2021
- Employees
- 10
- Website
- sweetech.fr/
- Ownership
- Privately Held (backing)
Sweetech (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sweetech (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sweetech (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.